Based on the results of the phase III ARAMIS trial that demonstrated significant improvement in metastasis-free survival, the U.S. Food and Drug Administration approved darolutamide under priority review on July 30, 2019. Darolutamide is approved for nonmetastatic, castration-resistant prostate cancer in men receiving concurrent gonadotropin-releasing hormone therapy or who have had bilateral orchiectomy.
Jill works as an oncology nurse in a large community hospital. While attending a family gathering, her uncle proudly tells her that he and his 17-year-old son are using e-cigarettes to help them stop smoking traditional cigarettes. He comments that his wife now allows them to “smoke” in the house and car because the vapor is relatively odor free.
By rebalancing the immune system and re-engaging mechanisms that tumor cells have shut off, immunotherapies such as immune checkpoint inhibitors enable patients’ own bodies to fight their cancers for them. But those same mechanisms can also result in immune-related adverse events (irAEs).
Better care. Smarter spending. Healthier people. Those are the three hallmark goals of the Oncology Care Model, a value-based payment system developed by the Centers for Medicare and Medicaid Service’s Center for Innovation.
E-cigarettes, initially introduced as a potential step-down smoking cessation strategy, have become a pervasive part of American culture—especially among users younger than 18 years of age. The rise in vaping rates has become so alarming that the U.S. surgeon general issued a statement declaring youth e-cigarette use a national epidemic. In light of Centers for Disease Control and Prevention reports of increasing vaping-related lung disease and death, ONS released its revised position statement, “Potential Adverse Health Consequences From Use of E-Cigarettes and Vaping,” to highlight the negative effects of vaping, emphasize the lack of regulatory oversight, and better inform oncology nursing practice for patients and their families.